MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Accumulated OCI · Q3 FY2026 · quarter ended Sep 2026
Accumulated OCI turns negative
Q3 FY2026 Accumulated OCI was -$1.96M, compared with $154K a year earlier. Over 3 fiscal years it compounded at +356.8% a year.
Context
- Accumulated OCI amounted to 0.4% of total assets at the end of Q3 FY2026, up 0.4 pp from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -1371.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 286K USD
- Year-over-year change
- +420.0%
- 3-year CAGR
- +356.8%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 286K | +420.0% |
| FY2024 | 2024-12-31 | 55K | -8.3% |
| FY2023 | 2023-12-31 | 60K | +1900.0% |
| FY2022 | 2022-12-31 | 3K | — |
Accumulated OCI vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -1371.4% is the lowest of 6, against a peer median of -4.4%.
- Accumulated OCI amounts to 0.4% of total assets for MBX, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €9.54M EUR | +852.1% | — | 0.4% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | -$24K USD | +4.0% | — | 0.0% | |
| Jun 2026 | -$1.15M USD | -594.6% | — | 0.2% | |
| Sep 2026 | -$1.74M USD | -88.3% | — | 0.4% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | -$1.79M USD | — | — | 0.1% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | -$1.96M USD | -1371.4% | +356.8% | 0.4% |
| Mar 2026 | -$5.22M USD | -4.4% | — | 1.6% | |
| Peer median (excluding MBX) | — | -4.4% | — | 0.2% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.